Abstract
Cardiovascular disease(CVD)is an important cause of death in the worldIn recent years, due to a large number of experimental results, people gradually abandon the previous view the CVD is caused by hyperlipidemia, and the CVD is caused by a chronic, low-intensity inflammatory response in blood vessels. in which inflammation is thought to be a key facilitator.However, there are limits to the study of drugs that use CVD for excessive inflammation.The Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, conducted in 2017, successfully demonstrated that inflammation plays an important role in atherosclerotic disease. Canakinumab is an antibody that can effectively inhibit the activation of IL-1 beta. The results of the Cantos trial ushered in a new era of new treatments aimed at treating cardiovascular diseases.Although the targeted anti-AS effect of CANTOS is prominent, its efficacy does not significantly improve the mortality and infection rate of patients with cardiovascular disease.To this end, we collected relevant data of Carnaro umab in recent years. This paper will focus on its clinical application and analyze its advantages and disadvantages, and give the possible improvement and development direction.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
